Analysis of ET-A and ET-B receptors using an isolated perfused rat lung preparation.

Granström, Bengt; Nilsson, E; Hultkvist-Bengtsson, U; Edvinsson, Lars

Published in:
Acta Physiologica Scandinavica

DOI:
10.1111/j.1365-201X.2004.01275.x

2004

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Analysis of ET-A and ET-B receptors using an isolated perfused rat lung preparation

B. Granström,1,2 E. Nilsson,1 U. Hultkvist-Bengtsson3 and L. Edvinsson1
1 Department of Internal Medicine, Lund University Hospital, Lund, Sweden
2 Department of Pediatrics, Lund University Hospital, Lund, Sweden
3 GITA (GastroIntestinal Therapy Area), AstraZeneca R&D, Lund, Sweden

Received 12 March 2003, accepted 16 February 2004
Correspondence: B. Granström
MD, Department of Paediatrics, University Hospital, S-221 85
Lund, Sweden.

Abstract
Aims and Methods: The pulmonary and vascular effects of endothelin-1 receptor activation were studied in isolated perfused and ventilated lung preparations from rat. The responses to endothelin-1 (ET-1) and the endothelin B (ETB) receptor agonist sarafotoxin 6c (S6c) were characterized using the endothelin A (ETA)-receptor antagonist FR 139317, the ETB-receptor antagonist BQ 788 and the combined ETA/ETB-receptor antagonist Bosentan. The respiratory parameter airway conductance (Gaw) and the vascular parameter perfusion flow were analysed simultaneously.

Results: Concentration–response curves for ET-1 administered intra-arterially revealed that its most potent effect was on the vascular side while S6c had a more potent effect on airway conductance. ET-1, given as a bolus dose intra-arterially (100 μL of 0.2 nm), induced a strong- and long-lasting contraction of the vasculature while only a less pronounced contraction was seen in the airways. Neither of the antagonists had a significant effect per se on Gaw or perfusion flow. FR 139317 reduced the effect of ET-1 on perfusion flow by about 50%, while airway conductance was augmented. BQ 788 enhanced the decrease in perfusion flow by ET-1 while Gaw was not influenced. The combined ETA/ETB antagonist Bosentan powerfully prevented the ET-1-induced decrease in Gaw but did not alter its reduction in perfusion flow.

Conclusions: The potent effect of ET-1 on the vascular side of the lung is mediated mainly through ETA receptors, whereas both ETA and ETB receptors are involved in Gaw in the rat lung.

Keywords Bosentan, BQ 788, endothelin-1, ETA receptor, ETB receptor, FR 139317, rat bronchus.

Endothelin-1 (ET-1) is a potent vasoconstrictor, one of the three endothelin isoforms ET-1, ET-2 and ET-3 (Yanagisawa et al. 1988, Masaki et al. 1992). Their effects are mediated through two types of receptors: ETA and ETB (Arai et al. 1990, Sakurai et al. 1990). ET-1 has the same affinity for ETA and ETB receptors while Sarafotoxin 6c (S6c) preferentially activates ETB receptors (Masaki et al. 1992). The distribution of the receptor subtypes varies between species, between vascular regions and depends on size of vessels within the same species (Cardell et al. 1990, Adner et al. 1998). ET-1 is synthesized, stored, released and metabolized in the lungs of many species including rat (Rozengurt et al. 1990) and man (Mattoli et al. 1990), suggesting a role both in normal physiology and in pathophysiological processes. Thus, a number of studies in asthma have reported that the levels of ET-1 are increased both within the bronchial tree and in the plasma (Vittori et al. 1992, Redington et al. 1995). ETA and ETB receptors have been identified in lung tissue of
man and animals (Cardell et al. 1990, Adner et al. 1996). In rat airways there are equal proportions of contractile ETA and ETB receptors (Henry 1993). The other component of the lung, the vascular bed, shows a complex response to ET-1; in pulmonary arteries the constriction is mediated through ETA receptors and balanced by the release of endothelium-derived nitric oxide generating a relaxation via ETB receptors. However, ETB receptors mediate constriction in the intrapulmonary arteries (MacLean et al. 1994). Thus, the localization and response to ET-receptor activation in the pulmonary circulation is unclear.

The aim of the present study was to develop an ex vivo perfused lung set-up and to investigate the functional role of ETA and ETB receptors by studying the responses of ET-1 and S6c alone and in combination on vascular perfusion and on respiratory parameters (Shennib et al. 1998). The ETA antagonist FR 139317 (Cardell et al. 1993), the ETB antagonist BQ 788 (Ishikawa et al. 1994) and the combined ETA and ETB antagonist Bosentan (Clozel et al. 1994) were used alone or in combination to allow a more precise pharmacological characterization.

**Materials and methods**

**Isolated lung preparation**

Male Sprague–Dawley rats, weighing 200–250 g (Mölegaard, Ejby, Denmark), were used for the lung preparation. The study was approved by the Animal Ethics Committee, Lund University, Sweden. After arrival, the rats were acclimatized for 1 week under standardized temperature (21–22 °C), humidity (50–60%) and light conditions (12 : 12 light–dark) in the animal department (AstraZeneca R&D, Lund, Sweden) until used. Five animals were kept in each cage (Macrolon type IV) with litter (B&K Universal, Sollentuna, Sweden) with tap water and free access to pelleted food (lactamin R70; Lactamin, Vadstena, Sweden).

A modified isolated and buffer perfused rat lung model (IPL) with negative pressure ventilation was used for the study (Fig. 1). Experiments were randomized, one group for each treatment with ET-1/S6c with or without either antagonist. Animals were anaesthetized by an intraperitoneal injection of a mixture of Hypnorm® (fluanisone 8.25 mg kg−1, fentanyl citrate 0.26 mg kg−1; Janssen Animal Health, Buckinghamshire, UK), Dormicum® (midazolam 4.13 mg kg−1; Roche AB, Stockholm, Sweden) and water in volume ratio 1 : 1 : 2. Heparin® (500 IU; Lövens, Malmö, Sweden) was injected into the jugular vein to prevent thrombosis. An airway cannula (PE-240; Becton Dickinson, Parsippany, NJ, USA) was inserted into the trachea and connected to a small animal ventilator (TG-Instrument AB, Mölndal, Sweden). During the surgical procedure the lungs were ventilated with room air at a frequency of 80 breaths min−1. The animals were killed, the chest opened and the pulmonary artery and vein cannulated (PE-240). The lungs were carefully perfused with a modified Krebs–Ringer buffer solution (37 °C), disseted-free together with the heart and suspended by the trachea in a humidified jacketed artificial ‘thoracic’ glass chamber maintained at 37 °C. Ventilation was carried out using alternating negative pressure inside the chamber (∼0.1 to −1.2 kPa, 80 breaths min−1), relating the ambient atmosphere, with the aid of a Rodent Ventilator type 7025 (Ugo Basile Biological Research Apparatus, Varese, Italy). The lungs were perfused at a flow rate of about 10–15 mL min−1 using the hydrostatic force and single-pass perfusion. The pH of the buffer solution was maintained at 7.35–7.45 by adjustment with CO2. The tracheal airflow was measured with a pneumotachygraph type 8420 (Hans Rudolph, Kansas City, KS, USA) and a pressure transducer (AstraZeneca R&D). A second pressure transducer was used to measure the alternating negative pressure in the artificial ‘thoracic’ chamber for measurement of the transpulmonary pressure. Perfusion flow rate was measured with a T106 small animal flow meter with in-line flow probe 2N648 (Transonic Systems, Ithaca, NY, USA). The signals from the pressure transducers and the perfusion flow meter were amplified, transformed and recorded in a computer. Data on lung mechanics (tidal volume, dynamic compliance, airway conductance) were calculated in real time by
using data from the whole breath cycle, monitored and stored using an in-house designed PC program.

**Study design**

After isolation, the lung was allowed to stabilize for at least 15 min during single-pass perfusion with buffer before administration of drugs. During this stabilization period, data was collected every 5 min from 10 successive breath cycles. The system was thereafter switched to a recirculating system (50 mL perfusion buffer).

In the first study, the agonists ET-1 and S6c were examined in a dose–response manner in the concentration ranges 0.01–1 and 0.01–0.3 nmol, respectively, added to the vascular perfusion buffer.

In the second study, the antagonists (BQ 788, FR 139317 or Bosentan) were added to the vascular perfusion buffer 20 min before either of the agonists ET-1 (0.2 nmol) or S6c (0.1 nmol) were administered as single doses. Thereafter, the lungs were perfused for 2 h and the vascular parameters were measured every 15 min.

In the third study, the antagonists were examined during a prolonged exposure time in order to evaluate a possible tonic influence of ET on the pulmonary vasculature or airways. The antagonistic concentrations were selected on previous experiments (Cardell et al. 1993, Adner et al. 1998, Szok et al. 2001).

**Solutions and drugs**

The perfusion medium for the lung experiments was a modified Krebs–Ringer buffer with a pH of 7.4, saturated with 95% O2 and 5% CO2 and included NaCl 118 mM, KCl 4.7 mM, CaCl2 2.5 mM, MgSO4 1.2 mM, NaHCO3 24.9 mM, KH2PO4 1.2 mM, HEPES 10 mM, d-glucose 11 mM and 4.5% w/v bovine serum albumin (BSA; Beringwerke, Marburg, Germany). All chemicals above were of analytical grade (Sigma Aldrich Sweden AB, Stockholm, Sweden).

The following drugs were studied: ET-1, S6c, BQ 788 (Auspep, Parkville, Australia), FR 139317 (Fujisawa Pharmaceuticals, Osaka, Japan), Bosentan (La Roche). All agents were dissolved and further diluted in saline containing 1% BSA to avoid adhesion of peptides to vials. The peptides were used in the experiments within 60 min to avoid any possible degradation. Analytical-grade chemicals and twice-distilled water were used for preparing all solutions.

**Statistics**

Results are expressed as mean ± SEM. Significance analysis was calculated with Student’s t-test. Statistical significance was assumed when P < 0.05.

---

**Results**

**Agonists**

Perfusion with the solvent for up to 2 h did not significantly alter either airway conductance or the vascular perfusion flow (Fig. 2a, b). ET-1, given as a bolus dose (0.2 nmol) into a pulmonary artery, caused a very strong and persistent drop in the perfusion flow, followed by a smaller drop in the conductance in the airways (Gaw) (Fig. 2a, b). Similarly, infusion of ET-1 in increasing doses into the pulmonary artery caused a more potent drop in the perfusion flow than in Gaw (Fig. 3).

The selective ETb agonist S6c, given in increasing doses into the pulmonary artery, did not diminish the
perfusion flow until the higher doses were given. S6c resulted in a powerful drop in $G_{aw}$, which was more potent than when ET-1 was administered (Fig. 4).

Antagonists

None of the antagonists alone had any effect on the vascular tone or on $G_{aw}$ in the doses studied (Fig. 5a, b). The ET$_A$-receptor antagonist FR 139317 diminished the ET-1-induced fall in perfusion flow ($P < 0.05$), however, the fall in $G_{aw}$ was augmented (Fig. 2a, b). On the other hand, the selective ET$_B$-antagonist BQ 788 augmented the fall in perfusion caused by ET-1 ($P < 0.05$) while the $G_{aw}$ was not influenced. Bosentan, the combined ETA- and ETB-receptor antagonist, almost totally blocked the fall in perfusion flow induced by ET-1 ($P < 0.05$). The effect was more pronounced than the response seen following FR139317 administration, while the $G_{aw}$ was only slightly affected (Fig. 2a, b).

Discussion

Due to high concentration of predominantly ET$_A$ receptors on the smooth muscle cells in the pulmonary
vascular system (Bonvallet et al. 1993), ET-1 has a strong effect on the vascular bed. Consequently, ET-1 administrated into the pulmonary artery resulted in strong, almost irreversible, binding to the receptors on the smooth muscles in the vascular wall (Westcott et al. 1990), which induced a persistent contraction, i.e. a profound and long-lasting decrease in the lung perfusion flow. An essential requirement for the effect of a substance is an uncompromised access to the receptor. When ET-1 is administered on the vascular side, the binding primarily takes place in the ET receptors on the endothelial and smooth muscle cells within the vascular walls. However, there is a rapid reduction in the circulation, which possibly compromises the further access of ET-1 to the pulmonary side. In this situation, the putatively reduced amounts of ET-1 may pass less well to the receptors in the airway system, explaining the weaker bronchial contraction than what would be expected. Furthermore, attenuation of ET-1 binding and vasoconstriction by the ETα antagonist FR 139317 should improve the possibility for ET-1 binding to the ETβ receptors in the airways resulting in a stronger decrease in airway conduction.

In our study, ET-1 given either as a bolus dose or in a dose–response manner induced a fast and persistent drop in perfusion flow. The decrease in flow was persistent during 2 h after administration (until experiments were finished, data not shown). The long-lasting decrease in perfusion flow may be the main factor why no reduction of the Gsw was seen later in time and when higher doses of ET-1 were given. However, S6c, which is a highly selective ETβ agonist (Adner et al. 1998), resulted primarily in a more potent effect on Gsw than in diminishing the perfusion flow. The same observations were made using another ETβ agonist, IRL 1620, where only a minor effect was seen on the vascular perfusion (Uhlig et al. 1995). In this situation, the lung circulation is not compromised and only small amounts of S6c will bind to the vascular epithelium. In addition, it is likely that the endothelial effect of ETβ receptor stimulation results in relaxation of the underlying smooth muscle cells (Szok et al. 2001). The contractile ETβ receptors in the airways can then be reached and the main effect observed was a powerful drop in the Gsw; this was more potent than the response noted upon ET-1 administration. The contractile effect of S6c acting via ETβ receptors has a different mode of action when compared with the ETα-mediated contraction. The contraction appears within minutes but with an obvious tachyphylaxia (O’Donnell & Kay 1995) and after about 2 h the contractile response following S6c has disappeared.

Considering that the ETα receptors are the dominant endothelin receptor in the vessels (90% vs. 10%) and the proportions of the ET receptors are equal in the airways, the most apparent effect of ETα antagonists was seen in the vessels (Lal et al. 1995). The ETα-receptor antagonist FR 139317 was added to the recirculating perfusion 20 min before administration of ET-1. The vasoconstriction elicited, compared with control, was attenuated but the bronchial constriction was rapid and strong. This may be explained by the dominant ETβ receptors in the airways and blocking of dilatory ETα receptors by FR 139317 (Granstrom et al. 1997).

The ETβ antagonist BQ 788 had an opposite effect when compared with FR 139317 on the perfusion flow induced by ET-1; the ET-1-induced reduction in flow was more marked (Fig. 2), suggesting that a week ETβ-induced relaxation had been blocked (Szok et al. 2001). There was no obvious effect of BQ 788 on the ET-1-induced effect on airway conductance. These results suggest less contractile activity of ETα than of ETβ receptors in the rat airways. Bosentan inhibited most of the effects of ET-1 on the perfusion flow. The reason why Bosentan had a significantly stronger blockage effect than FR 139317 on the ET-1 effect of the perfusion flow might simply be that the dose given was somewhat higher in terms of antagonistic effect. The antagonism of ET receptors in the bronchial tree seems to be partial. The persistent almost normal circulation gives good access for ET-1 to the still remaining non-antagonized receptors in the bronchial tree and results in a response that is similar to that of ET-1 without any antagonist used.

Many studies have indicated that ET-1 is an important neuropeptide in lung diseases such as asthma bronchiale (Goldie et al. 1996). It is important to recognize that in lung diseases ET receptors are upregulated (Moller et al. 1997, Granstrom et al. 2004), which further adds to their importance in pulmonary obstructive disease. The present study is a description of an isolated lung model in which complex interactions between the airways and the vascular tree can be characterized. We have shown that the use of isolated, perfused and ventilated lungs from the rat is a useful model for studying both the vascular and pulmonary effects of ET receptor agonists and antagonists. The vasculature contained mainly a contractile ETα receptor while the airway conductance involves both ETα and ETβ receptors. The results demonstrate the importance of how drugs are administrated.

This work was supported by a grant from the Swedish Research Council (project no. 05958).

References

Role of endothelin receptors in the rat lung • B Granström et al.


